Shares in Oldwick, N.J.-based Provention Bio began trading today following the close of its $64 million initial public offering last week. The biopharmaceutical company, lead by co-founder & CEO Ashleigh Palmer, is developing a number of products that aim to prevent or stop the spread of immune-mediated diseases, including Lupus, Crohn’s disease and Type I diabetes. […]
proventionbio
Provention Bio closes $64m IPO
Provention Bio yesterday closed its initial public offering, raising approximately $63.9 million. Funds from the round will help support the Oldwick, N.J.-based company’s clinical-stage biopharmaceuticals that aim to prevent or intercept immune-mediated diseases. Provention Bio said that it expects shares of its common stock will begin trading on Nasdaq under the ticker symbol “PRVB” next […]
Provention Bio wants to stop Type I diabetes – with a vaccine
Before he co-founded Provention Bio, Ashleigh Palmer worked on inhaled nitric oxide for infants with respiratory failure. After the company was sold for $1.2 billion to a Baxter-led consortium, Palmer noticed there was apprehension about conducting clinical trials with neonates. He was concerned that the inhaled NO assets were slated to fall to the wayside. […]
Provention Bio evaluates vaccine to prevent onset of T1D
Provention Bio said today that it licensed an enterovirus vaccine platform that it plans to evaluate as a way to prevent the onset of Type I diabetes by vaccinating against infection by a coxsackievirus B pathogen. Previous work has shown that CVB infection could be responsible for 50% of Type I diabetes cases worldwide, according […]
